Evofem Biosciences, Inc.:
Evofem Biosciences (EVFM) is developing Amphora®, a Multipurpose Vaginal pH Regulator (MVP-R) and non-hormonal, on-demand, woman-controlled vaginal gel for birth control and the prevention of urogenital acquisition of certain STIs. In December 2018, the Company reported positive top-line data from its confirmatory Phase 3 study in ~1400 women in the US; anticipates a 2H19 NDA submission, with a potential US launch in 2020. Secured $30M strategic investment from PDL BioSciences (PDLI) in April 2019 for 6.7M shares at $4.50 (26% premium to prior day close) and 25% warrant coverage. Second tranche of financing up to $50M expected to close on or before June 10, 2019.
United Kingdom, USA
Men's Health, Women's Health
100MM - 500MM
12400 High Bluff Drive
San Diego, CA 92130
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by